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Introduction
The human papilloma virus (HPV) is one of the 
most important carcinogenic factors, classified as 
a group 1 carcinogen according to the criteria of 
the International Agency for Research on Cancer. 
Different high-risk HPV types are causally associ-
ated with about 5% of all cancers, 10% of female 
cancers, and 16% of cancers of women in coun-
tries with limited resources [De Flora and 
Bonanni, 2011; de Martel et  al. 2012; Forman 
et al. 2012] (Table 1).
The development of two vaccines able to prevent 
persistent HPV infections and the evolution to 
precancerous lesions has opened a new era in vac-
cinology and oncology. HPV vaccines are actually 
perceived as the first anticancer vaccines (those 
against hepatitis B were in reality the first vaccines 
directed against a tumour).
Due to the impossibility of measuring direct effi-
cacy against cancer for both ethical and 
time reasons, prevention of cervical intraepithelial 
neoplasia lesions of grades 2 or 3 (CIN2+) was 
considered as the best surrogate endpoint for pro-
tection. Clinical trials of both the quadrivalent 
(type 16, 18, 6 and 11 containing vaccine) and 
the bivalent (type 16 and 18 containing vaccine) 
reported results mainly as efficacy against the 
above endpoint [Future II Study Group, 2007; 
Paavonen et al. 2009].
Since 2007, recommendations have been issued 
in many industrialized countries on subjects to 
whom vaccination should actively be offered. 
Actual implementation was highly dependent on 
national factors, such as organization of the 
healthcare system and ways chosen to fund or 
reimburse vaccination offer [Bonanni et al. 2011].
In this review, we aim to provide evidence of the 
first results of the effectiveness of HPV immuni-
zation on HPV-related diseases, outline different 
recommendations from around the world, and 
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also identify priority subjects to whom vaccina-
tion is proposed and administered.
HPV vaccination effectiveness: general 
aspects
HPV vaccines are intended to prevent, as their 
primary objective, cervical and other genital can-
cers. As such, their effectiveness will be measura-
ble only in the long term, when sufficiently 
numerous cohorts of immunized adolescents will 
have reached the age when cancers are more fre-
quently diagnosed.
Since the natural history of the evolution from 
persistent infection to precancerous (CIN1–3) 
and cancerous lesions is well known [Goldie et al. 
2003], several model-based projections have been 
made about the impact of HPV-vaccination pro-
grammes on disease incidence, thus allowing the 
forecast of both clinical and economic outcomes 
of immunization before the two HPV vaccines 
were available on the market. Different modelling 
approaches were used (e.g. cohort, population 
dynamic and hybrid), but all simulations demon-
strated that universal pre-adolescent female 
immunization coupled with screening invariably 
substantially impacted on the incidence of cervi-
cal precancers and cancers, and was cost-effective 
even when only cervical cancer was considered, 
without also taking into account impact on the 
rarer cancers associated with HPV [Dasbach et al. 
2006]. Papers on impact models of HPV vaccina-
tion are continuously being produced to explore 
new possible target groups, such as adolescent 
males [Smith and Canfell, 2014] or, recently, the 
use of a reduced number of doses [Jit et al. 2014].
However, it must not be forgotten that the impact 
of HPV vaccination on conditions with a shorter 
natural history compared with cancer is already 
possible a few years after universal immunization 
was implemented. In particular, comparison 
between vaccinated and nonvaccinated subjects 
with regard to persistent HPV infection, genital 
warts (for the quadrivalent vaccine), and 
precancerous lesions (CIN2+) has started to 
supply intriguing data on the effectiveness of 
HPV vaccination.
Caution in the evaluation of results is always 
needed, since sources of bias and misinterpreta-
tion are possible. As a matter of fact, monitoring 
prevalent infections implies sampling, detecting 
and genotyping HPV from the infection site, and 
the recent changes occurring in many countries in 
the recommendations on the age of initiation of 
screening, its intervals and tests to be used can 
affect the possibility of detection of infections and 
lesions, especially when methodological changes 
occur during the follow-up time. In addition, with 
regard to impact on genital warts, it is worth 
underlying that such lesions are not subject to 
notification in many countries, and their diagno-
sis is highly variable and dependent on health 
organization and social factors [Hariri et  al. 
2013]. However, despite such limitations, data 
are accumulating in several countries that provide 
proof of the effectiveness of HPV vaccination.
Effectiveness of HPV vaccination: examples 
across the world
Examples of the effectiveness of HPV vaccination 
are available from different countries, but there is 
no doubt that Australia is the country where 
immunization programmes were most compre-
hensive, and where high coverage in a considera-
ble number of young females was reached in a 
short time. Coverage with three doses of quad-
rivalent HPV vaccine in female cohorts ranged 
from 30% in the age groups 20–26 years and 73% 
in 12–13-year-old groups, respectively (with 
intermediate age groups showing progressively 
higher coverage with decreasing age). The corre-
sponding figures for uptake of at least one dose 
were 52% and 83% [Gertig et al. 2011].
A comparative study on HPV-type prevalence in 
Pap smears in Australian women aged 18–24 
years in the prevaccination period (2005–2007) 
and in the postvaccination period (2010–2011) 
using the same recruitment and testing strategies 
showed that the prevalence of vaccine HPV geno-
types (6, 11, 16 and 18) was significantly lower in 
the postvaccine sample than in the prevaccine 
sample (6.7 versus 28.7%; p < 0.001), with a 
lower prevalence observed in both vaccinated and 
unvaccinated women compared with the prevac-
cine population (5.0% [adjusted odds ratio (OR): 
0.11; 95% confidence interval (CI): 0.06–0.21] 
Table 1. Proportion of cancers attributable to 
persistent human papilloma virus infection.
5% of cancers
10% of cancers in women
16% of cancers in women living in developing 
countries
P Bonanni, A Bechini et al.
http://tav.sagepub.com 5
and 15.8% [adjusted OR: 0.42; 95% CI: 0.19–
0.93], respectively) [Tabrizi et al. 2012].
Also the impact on genital warts was clear. In a 
study evaluating the trend of Australian national 
surveillance data between 2004 and 2011 in more 
than 85,000 subjects, a dramatic decline was 
observed in the proportions of women younger 
than 21 years and those aged 21–30 years diag-
nosed with genital warts which, respectively, 
changed from 11.5% in 2007 to 0.85% in 2011 
(a 92.6% decline; p < 0.001), and from 11.3% in 
2007 to 3.1% in 2011 (a 72.6% decline; 
p < 0.001). By contrast, no significant decrease in 
genital warts diagnoses was registered in women 
older than 30 years. The indirect effect of univer-
sal immunization was also detected in heterosex-
ual men younger than 21 years and those aged 
21–30 years, for whom a 81.8 and 51.1% decrease 
of genital warts, respectively, was detected in the 
same period (p < 0.001). No decline in wart diag-
noses was registered in heterosexual men over 30 
years of age [Ali et al. 2013].
A third study from Australia was also able to show 
the decrease of high-grade cervical abnormalities 
(HGA) (CIN2+ or adenocarcinoma in situ) in 
women younger than 18 years involved in the vac-
cination programme when comparing the period 
2003–2007 (prevaccination) with the period 
2007–2009 (postvaccination). Such a decline 
from an incidence of 0.85% in 2006 to 0.22% in 
2009 represents a more than 50% decline in inci-
dence (p = 0.003). A quantitative comparison of 
linear trends also showed a significant decrease in 
HGA incidence after the introduction of the vac-
cination programme in individuals aged 17 years 
or younger, but no significant decrease in those 
aged 18–20 years. Although the ecological nature 
of the study does not prove a causal link between 
the decrease of HGA incidence and implementa-
tion of HPV vaccination, it is nevertheless very 
plausible that the two phenomena are strongly 
related, since no change was recorded in nonvac-
cinated cohorts [Brotherton et al. 2011].
Evidence of the early impact of HPV vaccination 
is available not only from Australia, but also from 
northern European countries. A study in Denmark 
demonstrated that, whereas a 2% annual increase 
of genital warts had been registered in the years 
preceding immunization, they virtually disap-
peared in girls aged 16–17 years when, after the 
introduction of vaccination, coverage reached 
85% in a short time. No indirect impact on warts 
in males has been registered up to now [Baandrup 
et al. 2013].
All Nordic countries have implemented a long-
term surveillance system to follow up women vac-
cinated in the first vaccine trials of the quadrivalent 
HPV vaccine. Since all women in the placebo arm 
of the Future II vaccine trial were immunized 
after 60 months of observation for ethical reasons 
[Olsson et  al. 2007], it is no longer possible to 
calculate vaccine efficacy (VE). However, it is 
noteworthy that no case of breakthrough HPV 
16/18-related CIN2+ occurred in women belong-
ing to the vaccine arm up to 8 years after immu-
nization [Kjaer et al. 2012].
In the USA, coverage with HPV vaccine is low in 
girls targeted by the vaccination recommenda-
tions (three-dose coverage in 2010 was only 32% 
among 13–17-year-olds). Nevertheless using data 
from the National Health and Nutrition 
Examinations Surveys, a clear decline (56%) of 
vaccine-type HPV infections between 2003–2006 
and 2007–2010 was registered in those aged 
 14–19 years. Vaccine effectiveness of at least one 
dose against such an endpoint gave results as high 
as 82% [Markowitz et al. 2013].
HPV vaccines have shown a variable degree of 
cross protection in clinical trials. However, an 
unexpected effect on 6-month persistent infec-
tions has been recently described in the Papilloma 
Trial Against Cancer In Young Adults 
(PATRICIA) study for the bivalent vaccine 
against HPV types responsible for genital warts. 
VE was 34.5% against combined HPV 6/11, 
34.9% against HPV 6, and 49.5% for HPV 74 (all 
statistically significant results). An ecological 
study on the impact of the bivalent vaccine on 
genital warts incidence in the UK seems to con-
firm the trial data. As a matter of fact, between 
2008 and 2011, a universal programme with the 
bivalent HPV vaccine was implemented in 
12-year-old girls, reaching more than 80% cover-
age, supplemented by a catch-up strategy up to 
18 years (more than 40% coverage). Genital 
warts, which had increased steadily from the 
1970s until 2009, showed a decrease since then, 
with a calculated 11–16% effectiveness of the vac-
cine in young women aged 18 years and 15 years, 
respectively [Howell-Jones et al. 2013; Szarewski 
et al. 2013].
HPV is not only responsible for genital lesions, 
but is also a considerable cause of morbidity and 
Therapeutic Advances in Vaccines 3(1)
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mortality for head and neck cancers. More than 
11,000 such cancer cases attributable to HPV are 
estimated to occur every year in the USA, with a 
4/1 rate for males compared with females. 
Whether HPV vaccines will be able to prevent 
HPV-related head and neck cancers still remains 
undemonstrated. Actually, it is not possible to 
perform clinical trials due to the absence of an 
early marker of disease, and therefore only popu-
lation-based epidemiological studies will be able 
to address this issue in the next 1–2 decades. 
However, vaccine coverage has been foreseen by 
the scientific community as well as by the Centers 
for Disease Control and Prevention (CDC) to 
have an impact on the incidence and mortality of 
more exploratory outcomes, such as head and 
neck cancers [Brotherton and Gertig, 2011; 
CDC, 2012].
A first positive indication of the potential role of 
HPV immunization comes from a recent study 
performed during a clinical trial of the bivalent 
vaccine in Costa Rica. At the final study visit, 
5840 participants provided oral specimens 
(91.9% of eligible women) to evaluate VE against 
oral infections. Primary analysis evaluated preva-
lent oral HPV infection among all vaccinated 
women with oral and cervical HPV results. 
Approximately 4 years after vaccination, there 
were 15 prevalent HPV 16/18 infections in the 
control group and one in the vaccine group, for 
an estimated VE of 93.3% (95% CI: 63–100%). 
Corresponding VE against prevalent cervical 
HPV 16/18 infection for the same cohort at the 
same visit was 72.0% (95% CI: 63–79%) (p versus 
oral VE = 0·04).These results suggest that the 
bivalent HPV vaccine affords strong protection 
against oral HPV 16/18 infection, with potentially 
important implications for the prevention of 
increasingly common HPV-associated oropharyn-
geal cancer [Herrero et al. 2013].
Studies have been committed by regulatory agen-
cies to exclude the possibility that, under immu-
nological pressure in highly vaccinated 
populations, types of HPV not included in vac-
cines might emerge as a cause of precancerous 
and cancerous lesions, thus filling an ecological 
niche left open by immunization programmes. 
Such researches are under way and will add 
important information in the near future. 
However, some characteristics of HPV viruses 
(like the frequent possibility of being infected 
simultaneously by different HPV types) make it 
very unlikely that a replacement effect like that 
described for some encapsulated bacteria might 
occur after the implementation of routine HPV 
vaccination programmes.
The new two-dose vaccination schedule
The opportunity to reduce the number of doses 
needed to confer protection against HPV-related 
diseases has a double potential advantage: it 
makes coverage targets easier and saves money 
that could be used to expand target cohorts for 
immunization.
Two studies were performed on the potential use 
of a two-dose schedule with the bivalent vaccine, 
firstly a ‘proof of concept’ phase I/II trial (HPV-
048) [Romanowski et al. 2011], and subsequently 
a confirmatory, phase III trial (HPV-070) 
[Puthanakit et al. 2013]. The first study investi-
gated the two-dose schedules using the licensed 
20/20 μg of HPV 16 and HPV 18 L1 protein 
virus-like particles or an alternative formulation 
containing 40 μg of each antigen, compared with 
the licensed three-dose schedule. Healthy females 
stratified by age (9–14, 15–19, 20–25 years) were 
randomized to receive two doses of 20/20 vaccine 
at months (M) 0,6 (n = 240), 40/40 vaccine at 
M0,6 (n = 241), or 40/40 vaccine at M0,2 
 (n  =  240), or three doses of 20/20 vaccine at 
M0,1,6 (licensed schedule/formulation, n = 239). 
One month after the last dose, the three-dose 
schedule was not immunologically superior to the 
two-dose schedules except in the 40/40 vaccine 
M0,2 group for HPV 16 (lower limit of 95% CI 
geometric mean antibody titre [GMT] ratio [two-
dose/three-dose] < 0.5). For both HPV 16 and 
HPV 18, the two-dose schedules in girls 9–14 
years were immunologically noninferior to the 
three-dose schedule in women 15–25 years (the 
age group in which efficacy has been demon-
strated) (upper limit of 95% CI for GMT ratio 
[three-dose/two-dose] < 2) 1 month after the last 
dose. At month 24, noninferiority was maintained 
for the two-dose M0,6 schedules in girls 9–14 
years versus the three-dose schedule in women 
15–25 years [Goldie et  al. 2003]. Antibody 
response was recently reported to be still high at 
the 48-month follow-up visit in all groups 
[Romanowski et al. 2013].
The confirmatory phase III trial aimed, as a pri-
mary objective, at demonstrating noninferiority in 
enzyme-linked immunosorbent assay (ELISA) 
for the two-dose schedule (M0,6) in 9–14-year-
old girls versus the three-dose schedule (M0,1,6) 
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in 15–25-year-old women for both seroconver-
sion rates and GMTs. Secondary objectives were 
to measure functional antibody response through 
pseudovirion-based neutralization assay (PBNA) 
and cell-mediated immunity (CMI) including, for 
the latter evaluation, cross-protective antibodies 
against HPV 31/45. In the according-to-protocol 
population, noninferiority of the two-dose sched-
ule in 9–14-year-olds versus the three-dose sched-
ule in 15–25-year-olds was demonstrated for 
HPV 16/18 ELISA antibody response. At least 
98.9% of initially seronegative subjects serocon-
verted for anti-HPV 16/18/31/45 antibodies 
(ELISA). Anti-HPV 16/18/31/45 GMT (ELISA) 
and CMI responses were similar (descriptive 
analysis) between two-dose and three-dose 
groups. HPV 16/18 neutralizing antibody 
responses (PBNA) appeared higher in the two-
dose group than in the three-dose group. The 
European Medicine Agency (EMA) approved the 
change for the indication of the bivalent HPV 
vaccine to a two-dose schedule for girls aged 9–14 
years on 20 December 2013.
With regards to the quadrivalent HPV vaccine, no 
‘ad hoc’ study was planned by the producer to 
support a change of schedule in young girls. 
However, some countries independently opted 
for an off-label use of the vaccine, proposing the 
use of a two-dose schedule, possibly followed by a 
booster dose some years later. In particular, a ran-
domized, phase III postlicensure noninferiority 
study was conducted in Canada on 830 age-strat-
ified female subjects [Dobson et al. 2013]. Girls 
aged 9–13 years were randomized 1:1 to receive 
three doses of quadrivalent HPV vaccine at M0, 
2, 6 (n = 261) or two doses at M0,6 (n = 259). 
Young women (16–26 years) received three doses 
at M0,2,6 (n = 310). Antibody levels were meas-
ured at M0,7,18,24,36. The results showed that 
the GMT ratios were noninferior for girls (two 
doses) to women (three doses): 2.07 (95% CI: 
1.62–2.65) for HPV 16 and 1.76 (95% CI: 1.41–
2.19) for HPV 18. Girls (three doses) had GMT 
responses 1 month after the last vaccination for 
HPV 16 of 7736 mMU/mL (95% CI: 6651–8999) 
and HPV 18 of 1730 mMU/mL (95% CI: 1512–
1980). The GMT ratios were noninferior for girls 
(two doses) to girls (three doses): 0.95 (95% CI: 
0.73–1.23) for HPV 16 and 0.68 (95% CI: 0.54–
0.85) for HPV 18. The GMT ratios for girls (two 
doses) to women (three doses) remained noninfe-
rior for all genotypes at month 36 of follow up. 
Antibody responses in girls were noninferior after 
two doses versus three doses for all four vaccine 
genotypes at month 7, but not for HPV 18 by 
month 24 or HPV 6 by month 36. Based on the 
presentation of the comparative results with the 
two-dose schedule in 9–13-year-old girls versus 
the three-dose schedule in young women, on 27 
February 2014, the Committee for Human 
Medicinal Products of the EMA granted a posi-
tive opinion on the possibility of adopting a two-
dose schedule with the quadrivalent HPV vaccine 
in girls in the age range 9–13 years. The new EMA 
indications for the quadrivalent HPV vaccine allow 
for a two-dose (M0,6) or three-dose (M0,  2,  6) 
schedule in subjects aged 9–13 years.
HPV vaccination recommendations in 
different countries
Recommendations for HPV vaccination of the 
primary cohort have been issued in nearly all 
western European countries, and nationally/
regionally funded vaccination programmes for 
HPV have been introduced in most western 
European countries, with some exceptions (e.g. 
Austria was the first country to issue national rec-
ommendations in November 2006, but never 
publicly funded the programme).
In Europe, universal HPV vaccination of female 
adolescents was first introduced in 2007 in 
Belgium, France and Germany. In the subsequent 
year, programmes were also started in Greece, 
Luxembourg, the Netherlands, Italy, Romania, 
Spain and Switzerland; in 2009 in Denmark, 
Norway, Portugal, San Marino, Macedonia and 
the UK [Bonanni et al. 2011].
As of May 2013, 45 countries have introduced 
HPV vaccination at the global level (Figure 1) 
[World Health Organization, 2014]. Most of these 
are developed countries, but given that the global 
burden of cervical cancer falls heaviest on devel-
oping countries, there is still a great need for more 
countries to introduce HPV vaccination as part of 
a national public-health strategy that includes a 
comprehensive approach to prevention and con-
trol of cervical cancer.
In 2013, a record-low price for HPV vaccines was 
negotiated by the Global Alliance for Vaccines 
and Immunization (GAVI) for countries eligible 
for support, opening the door for millions of girls 
in the world’s poorest countries to be immunized 
against HPV. The US$4.50 vaccine represents a 
two-thirds decrease on the lowest previously avail-
able public price. GAVI’s support for HPV 
Therapeutic Advances in Vaccines 3(1)
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vaccines will enable a bridging of the gap between 
rich and poor countries, by making HPV vaccines 
available where girls need them the most, thus 
preventing the infection that causes this disease.
Eleven mainly sub-Saharan African countries 
were approved in 2013 to introduce HPV vac-
cines with GAVI support: Ghana, Kenya, Laos, 
Madagascar, Malawi, Mozambique, Niger, Sierra 
Leone, Tanzania and Zimbabwe, with Rwanda 
being the first country to roll out HPV vaccines 
nationally with GAVI support in 2014. Another 
10 countries are running or will run demonstra-
tion programmes over the next 3 years: Benin, 
Burundi, Cameroon, Cote d’Ivoire, Gambia, 
Liberia, Mali, Senegal, Solomon Islands and Togo 
(Figure 2). The demonstration projects provide 
countries with an opportunity to gain experience 
in reaching girls with vaccines outside the usual 
routine immunization schedule and to make 
informed decisions about whether to apply for a 
national introduction. The wide reach of the 
immunization programmes also provides an 
opportunity for countries to implement other 
health interventions that may benefit young ado-
lescent girls.
By 2015, GAVI plans to support the vaccination 
of 1 million girls in more than 20 countries and 
expects these numbers to accelerate dramatically, 
with the goal of more than 30 million girls vacci-
nated in over 40 countries by 2020.
Coverage data are highly variable among industri-
alized countries with consolidated programmes, 
with higher coverage usually being reached in 
countries providing vaccination through a well-
organized school-health system. However, good 
results were obtained also in some countries where 
girls were invited to vaccination services outside 
schools [Bonanni et al. 2011]. Nevertheless, more 
efforts are needed to make HPV vaccine uptake 
nearly universal in target groups. Communication 
should clearly highlight that severe forms of can-
cer can be avoided by vaccination, an opportunity 
that should not be missed.
Vaccination acceptance and coverage rates: 
an open issue
In spite of the excellent efficacy, effectiveness and 
safety profile of HPV vaccines, acceptance and 
coverage rates are still far from optimal in the 
The boundaries and names shown and the designations used on 
this map do not imply the expression of any opinion whatsoever on 
the part of the World Health Organization concerning the legal 
status of any country, territory, city or area or of its authorities, or 
concerning the delimitation of its frontiers or boundaries.  Dotted 
lines on maps represent approximate border lines for which there 
may not yet be full agreement. 
WHO 2013. All rights reserved
Data Source: WHO/IVB Database, as at  29 May 2013 
Map production: Immunization Vaccines and Biologicals, 
(IVB), World Health Organization
Date of  slide: 29 May 2013
Not Available, Not Introduced /No Plans 
(145 countries or 75%)
Not applicable
Planned introductions in 2013 (4 countries or 2%)
Introduced to date (45 countries or  23%)
* Includes partial introduction
0 1,700 3,400850 Kilometers
Figure 1. Countries with human papilloma virus vaccine in the national immunization programme and 
planned introductions, 2013 (source: World Health Organization).
Introduced: Argentina, Australia, Austria, Belgium, Bhutan, Brazil, Brunei Darussalam, Canada, Colombia, Cook Islands, 
Czech Republic, Denmark, Fiji, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Japan, Kiribati, Latvia, Lesotho, 
Luxembourg, Macedonia, Malaysia, Marshall Islands, Mexico, Micronesia (Federated States of), the Netherlands, New 
Zealand, Norway, Palau, Panama, Paraguay, Portugal, Rwanda, San Marino, Singapore, Slovenia, Spain, Sweden, 
Switzerland, Trinidad and Tobago, Uganda, UK, USA, Uruguay.
Partial introduction: Brazil, Kiribati, Uganda.
2013 planned introductions: Kazakhstan, Libya, Suriname, Vanuatu.
Peru introduced the vaccine in 2011, then it was suspended, possible re-introduction in the next 2 years.
Some countries are running demonstration projects. They are not included.
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majority of countries that introduced routine 
active immunization programmes.
According to the updated European Centre for 
Disease Prevention and Control (ECDC) guid-
ance on the introduction of HPV vaccines in 
European countries (2012), there are several rea-
sons for such low uptake. Among them, the most 
relevant seem to be the scarce knowledge of HPV 
and the HPV vaccine, the high costs of vaccina-
tion where they are covered by the recipient, a 
perceived low efficacy of the vaccine, and alleged 
and real adverse events to vaccines. Moreover, 
many studies underlined the factors that are bar-
riers to parental acceptance of HPV immuniza-
tion including a decreasing awareness of 
vaccination after the initial knowledge when 
immunization programmes were introduced, per-
sisting concerns regarding safety and side effects, 
a perception of the vaccine in a similar vein to the 
oral contraceptive pill, with preference to post-
pone vaccine administration until their children 
are sexually active [ECDC, 2012]. In this respect, 
it is worth underlining that a study on girls immu-
nized at 11–12 years of age in a large managed 
care organization and followed for up to 3 years 
showed that HPV vaccination at the recom-
mended ages was not associated with increased 
sexual activity-related outcome rates [Bednarczyk 
et al. 2012].
In order to increase coverage rates in all countries, 
necessary to obtain the crucial public-health results 
of HPV vaccination, parents need more informa-
tion and reassurance from healthcare workers on 
the safety and effectiveness of HPV vaccines. Policy 
programmes need to face parents’ concerns and 
communicate the appropriate information in a 
simple and easily understandable way. Moreover, 
attitudes, knowledge and practices of healthcare 
professionals towards vaccination should be stud-
ied and properly addressed through formative ini-
tiatives whenever needed [ECDC, 2012].
Vaccination of older women and males: 
opportunities and limits
Vaccination of naïve adolescent girls is without 
doubt the priority use of HPV vaccines, given 
their nearly 100% efficacy in this population. 
Figure 2. Countries introducing human papilloma virus vaccination with the support of the Global Alliance for 
Vaccines and Immunization, 2014.
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However, vaccination of young women and also, 
from an individual perspective, relatively older 
women is an attractive option to confer protection 
against precancerous and cancerous lesions 
[Muñoz et al. 2009; Schwarz et al. 2009].
Immunizing catch-up cohorts of women is useful 
because: (a) the chance of being infected by all 
four or two HPV types included in the quadriva-
lent or bivalent vaccine is extremely low (< 1%); 
(b) HPV vaccines are effective against HPV types 
for which the subject has never been infected at 
the time of immunization; (c) there is evidence 
that vaccination is protective against HPV types 
for which women had a previous resolved infec-
tion (seropositive, but DNA negative).
All sexually active women are permanently 
exposed to new infections and it is not feasible to 
identify those at higher risk. HPV infections can 
recur, even with the same type. Moreover, given 
the decreasing effectiveness of the immune sys-
tem with aging, persistent infections may increase 
with relative frequency [Castle et al. 2005].
Past Health Technology Assessment evaluations 
have shown that a universal, free-of-charge offer 
of HPV vaccination may be a cost-effective option 
to enlarge immunization offer beyond adolescent 
girls [Capri et  al. 2007]. The decline in public-
health costs of a HPV vaccine dose registered in 
the last few years is progressively increasing the 
age limit for a cost-effective vaccination pro-
gramme in women.
With regard to male vaccination, it has been dem-
onstrated that the vaccine is able to prevent exter-
nal genital lesions (particularly genital warts) with 
more than 90% efficacy [Giuliano et al. 2011]. The 
impact and relevance of male vaccination is 
extremely high in homosexual men. The efficacy 
against intraepithelial anal lesions was calculated 
to be 92% after assignment of aetiology to vaccine 
HPV types [Palefsky et  al. 2011], and therefore 
active offer of HPV immunization to homosexual 
men is a priority. However, given the clear difficul-
ties in identifying sexual orientation in adolescent 
males and the traditional failures of risk-based 
approaches for all vaccinations [Bonanni, 2007], it 
seems that only through a universal approach to 
male HPV vaccination will it be possible to confer 
substantial protection to such a high-risk category.
In this respect, regarding universal adolescent male 
vaccination, economic evaluations performed 
some years ago suggested that, compared with 
adolescent female immunization, vaccination of 
boys would be economically unattractive, unless 
the impact of immunization on infection transmis-
sion is proven, and coverage with three doses in 
girls is low [Brisson et al. 2011]. However, in the 
meantime, vaccination costs have decreased dra-
matically, making the HPV vaccine a tool for 
broader application.
Presently, there are still disadvantages, but also 
relevant advantages concerning the addition of a 
cohort of adolescent boys to the current recom-
mendation of girl vaccination. The weaknesses of 
adolescent boy immunization are the inferior 
cost-effectiveness compared with girls, the official 
indication restricted to external genital lesions 
(warts), the difficulty of demonstrating HPV vac-
cine efficacy and effectiveness against head and 
neck cancers (that are more incident in males 
than in females, with a proportion of 2:1), the lack 
of any data on the potential uptake of HPV vac-
cination in males. The advantages would be the 
improved cost-effectiveness with lower costs of 
each dose, the increasing evidence on HPV-
related burden of disease in males, the likely 
(although undemonstrated) impact on male can-
cers and precancers, the lack of any alternative 
early diagnosis for males (no screening available) 
and the potentially easier acceptance of a gender-
neutral immunization programme.
Conclusion
HPV vaccination represents a landmark in the 
history of both vaccination and cancer preven-
tion. Immunization of adolescent girls has the 
potential to decrease dramatically cervical cancer 
incidence and mortality, both in the industrial-
ized world and the developing world, where 
screening programmes for early detection of pre-
cancerous lesions are often impossible to set up. 
However, even in the Western world, there are 
ample sectors of the female population where 
periodical screening for cervical cancer detection 
is not performed regularly or at all. The only real 
hope of defeating cervical cancer is to implement 
universal girl immunization in all countries, and 
to carry out all possible efforts, including strong 
communication initiatives, to convince parents 
and girls that acceptance of HPV vaccination 
offer is a fundamental step for better prevention 
in women. Moreover, evidence is accumulating 
that cervical cancer, with no doubt the most 
important HPV-related disease, is not the only 
P Bonanni, A Bechini et al.
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potential public-health objective of immunization. 
Public-health authorities are therefore confronted 
with the importance of evaluating every possible 
positive impact that HPV immunization can have 
on the health of the population, trying to invest in 
a larger target for vaccination programmes.
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